Table 1 Trial groups and schedule of vaccination, specimen collection, and endpoint measurement
Group | |||
|---|---|---|---|
Age | 3 + 0 Acquisition (n = 392) Immunogenicity (n = 112) | 1 + 1 Acquisition (n = 196) Immunogenicity—YF/PCV co-administration (n = 112) | 1 + 1 YFseparate Acquisition (n = 196) Immunogenicity—YF/PCV separate administration (n = 112) |
6 weeks | PCV13 NPS (n = 392) | PCV13 NPS (n = 196) | PCV13 NPS (n = 196) |
10 weeks | PCV13 | Blood IgG (n = 112) OPA (n = 60) | |
14 weeks | PCV13 | ||
18 weeks | Blood IgG (n = 112) OPA (n = 60) | ||
6 months | NPS (n = 392) | NPS (n = 196) | NPS (n = 196) |
9 months | YF Blood IgG (n = 112) NPS (n = 392) | YF and PCV13 Blood IgG (n = 56) NPS (n = 196) | PCV13 Blood IgG (n = 56) NPS (n = 196) |
10 months | Blood YFNA (n = 112) IgG (n = 112) OPA (n = 112) NPS and serotype-specific carriage density (n = 392) | Blood YFNA (n = 112) IgG (n = 112) OPA (n = 112) NPS and serotype-specific carriage density (n = 196) | YF Blood IgG (n = 112) NPS and serotype-specific carriage density (n = 196) |
11 months | NPS (n = 392) | NPS (n = 196) | Blood YFNA (n = 112) NPS (n = 196) |
12 months | NPS (n = 392) | NPS (n = 196) | NPS (n = 196) |
13 months | NPS (n = 392) | NPS (n = 196) | NPS (n = 196) |
14 months | NPS (n = 392) | NPS (n = 196) | NPS (n = 196) |
18 months | Blood IgG (n = 112) OPA (n = 112) NPS (n = 392) | Blood IgG (n = 112) OPA (n = 112) NPS (n = 196) | NPS (n = 196) |
23 months | NPS (n = 392) | NPS (n = 196) | NPS (n = 196) |
24 months | NPS (n = 392) | NPS (n = 196) | NPS (n = 196) |
25 months | NPS (n = 392) | NPS (n = 196) | NPS (n = 196) |
26 months | NPS (n = 392) | NPS (n = 196) | NPS (n = 196) |
27 months | NPS (n = 392) | NPS (n = 196) | NPS (n = 196) |
28 months | NPS (n = 392) | NPS (n = 196) | NPS (n = 196) |